- active not recruitingPHASE3
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
This study looks at a new combination treatment, talazoparib and enzalutamide, for men with advanced prostate cancer that has spread and become resistant to hormone therapy. We want to see if this combination works better than enzalutamide alone.
United States · Argentina · Australia - recruitingPHASE1, PHASE2
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
This study is testing a new treatment for advanced prostate cancer that has spread and isn't responding to usual hormone therapy. It's called 177Lu-rhPSMA-10.1 and uses radiation to target cancer cells. We want to see how safe and effective it is.
United States · Belgium · Germany